Abstract
An intensive search is underway for novel selective inhibitors of cyclo-oxygenase (COX)-2. These compounds promise to be potent anti-inflammatory agents with little gastrointestinal intolerance. Meloxicam, with some selectivity for COX-2, is already marketed, and at least two companies are carrying out clinical studies with selective inhibitors. A variety of potential successor compounds were presented at the 8th International Conference of the Inflammation Research Association (IRA) in Hershey, PA on 27 - 31 October 1996.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
